Clinical trials: Type 2 Diabetic
Diabetic Nephropathy
Effect of Sulodexide in Early Diabetic Nephropathy
The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
- Trial name
- NCT00130208
- Testing
- Sulodexide
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Keryx Biopharmaceuticals
Type 2 Diabetes Mellitus
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet…
- Trial name
- NCT00367055
- Testing
- rosiglitazone-metformin, Metformin, metformin+ gliclazide
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Diabetic Foot, Foot Ulcer
A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers
A multicenter, prospective, controlled clinical trial evaluating the efficacy of a single layer placental-based allograft and standard of care in the management of nonhealing diabetic foot ulcers.
- Conditions
- Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU
- Trial name
- NCT07159282
- Testing
- XWRAP
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Applied Biologics, LLC
Diabetes, Diabetes Mellitus, Type 2
Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers
This trial is conducted in Japan. The aim of this trial is to compare biphasic insulin aspart 70 (NN2000-Mix70) in subjects with type 2 diabetes with that of biphasic insulin aspart 30 (NN-X14Mix30) in healthy volunteers.
- Trial name
- NCT01538511
- Testing
- biphasic insulin aspart 70, biphasic insulin aspart 30
- Where
- Japan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type…
- Trial name
- NCT00455858
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Novo Nordisk A/S
Diabetic Kidney Disease (DKD)
Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease
The goal of this single-arm, open-label clinical trial is to evaluate the effects of subcutaneous autologous dendritic cell (DC) and lymphocyte administration on albuminuria and endothelial dysfunction in Type 2 Diabetes Mellitus…
- Trial name
- NCT06866158
- Testing
- Dendritic cell immunotherapy
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- PT. JES Kasih Nusantara Sejahterah
Diabetes Mellitus, Type 2
Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment
The purpose of this study is to compare the incidence of hospitalizations for infections among patients with type 2 diabetes mellitus who are new initiators of Saxagliptin and those who are new initiators of Oral Anti-Diabetic…
- Trial name
- NCT01086306
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Glufast On Insulin Glargine Trial in Type 2 DM
We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients…
- Trial name
- GLORIA (NCT00663884)
- Testing
- Mitiglinide, Voglibose
- Where
- South Korea
- Volunteers
- 167 people
- Sponsor
- JW Pharmaceutical
Diabetes Mellitus, Type 2
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Primary objective: To show an improvement in HbA1c control after 4 months of treatment with insulin glargine + Oral Anti Diabetic (OAD) in patients previously uncontrolled on premixed insulin (with OAD) Secondary objective…
- Trial name
- OPTIMIZATION (NCT00693771)
- Testing
- Insulin Glargine
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)
The purpose of the study is to assess how MK0767, compared to Metformin, performs in lowering blood glucose levels in patients whose Type II diabetes is not controlled by diet and exercise.
- Trial name
- NCT00543361
- Testing
- MK0767, Comparator: metformin
- Volunteers
- 382 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
The objective of the randomised part of the study is to investigate the efficacy and safety of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug naive or previously treated (4 weeks…
- Trial name
- NCT00798161
- Testing
- BI 1356, BI 1356 + metformin, Metformin
- Where
- 138 sites in Canada, Croatia and 12 more
- Volunteers
- 857 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus.
- Trial name
- LIXILAN JP-O1 (NCT02749890)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Lixisenatide (AVE0010), Oral anti-diabetic drugs
- Where
- 61 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Sanofi
Diabetic Foot Ulcer, Diabetic Foot
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
- Conditions
- Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic
- Trial name
- CAMPAIGN (NCT06600724)
- Testing
- Standard of Care, EPIEFFECT, EPIXPRESS
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- MiMedx Group, Inc.
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics…
- Trial name
- ACTION (NCT00097279)
- Testing
- biphasic insulin aspart, pioglitazone, metformin
- Where
- 73 sites in United States
- Volunteers
- 230 people
- Sponsor
- Novo Nordisk A/S
Obesity
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
- Trial name
- NCT00391196
- Testing
- CP-945,598, CP-945,598 Treatment B
- Where
- 91 sites in United States, Argentina and 9 more
- Volunteers
- 975 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
This study is the second administration of GSK1362885 in humans. GSK1362885 is a novel, potent inhibitor of human glycogen phosphorylase (GP) under development for the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01013766
- Testing
- GSK1362885
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Hypomagnesemia in Type 2 Diabetic Patients
MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10 mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.
- Trial name
- NCT03567824
- Testing
- Magnesium L-lactate dihydrate
- Volunteers
- 200 people
- Sponsor
- Pharmalyte Solutions LLC
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®
This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 30 FlexPen® under normal clinical practice conditions.
- Trial name
- NCT00709683
- Testing
- biphasic insulin aspart 30
- Where
- Tunisia
- Volunteers
- 216 people
- Sponsor
- Novo Nordisk A/S